100
Participants
Start Date
October 24, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2027
Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy
Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
Paclitaxel + Carboplatin + Radiotherapy
Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
RECRUITING
Liaoning Cancer Hospital and Institute, Shenyang
RECRUITING
Zhongshan Hospital Fudan University, Shanghai
RECRUITING
Tianjin Medical University Cancer Institute and Hospital, Tianjin
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Cancer Hospital of Shantou University Medical College, Shantou
Shanghai Zhongshan Hospital
OTHER